Drug intelligence / Profile preview

CG0161

Development stage: Preclinical
Lead developer: CG Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CG0161 is a preclinical **anti-CTLA-4 monoclonal antibody** being developed by **CG Oncology** as an immuno-oncology therapeutic. It is designed to bind **cytotoxic T-lymphocyte-associated protein 4** and function as a **checkpoint inhibitor**, with the goal of enhancing antitumor T-cell activity. Public descriptions indicate that CG0161 is a wholly owned program intended primarily for use in combination with the company\u2019s oncolytic immunotherapy **CG0070**, especially in **bladder cancer** and potentially other solid tumors, although no clinical-stage data, brand name, or public INN have been disclosed.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on CG0161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG0161.

Explore the full profile